Poll: Vote on the Top Abstracts to Watch at SABCS 2025

The San Antonio Breast Cancer Symposium (SABCS) will be held in San Antonio, Texas, December 9–12, 2025. This year, several abstracts across breast cancer are poised to be practice-changing.

To find out which abstracts are most important to Targeted Oncology readers, we’re launching a series of polls to identify the most exciting research results in hormone receptor-positive (HR+), HER2+, and triple-negative breast cancer (TNBC). Voting is now open on LinkedIn and X.

What Are the Top Abstracts to Watch in HR+ Nonmetastatic Breast Cancer at SABCS 2025?

Poll 1: Which of these HR+ nonmetastatic breast cancer abstracts are you most anticipating at SABCS 2025?

Vote Now: X | LinkedIn

GS1-10: Giredestrant vs standard-of-care endocrine therapy as adjuvant treatment for patients with estrogen receptor-positive (ER+), HER2-negative early breast cancer: Results from the global phase 3 lidERA breast cancer trial

PS1-08-08: MonarchE: subgroup analysis of adjuvant abemaciclib plus endocrine therapy for HR+, HER–, high-risk early breast cancer by nodal status

GS2-05: Primary results from the HR+/HER2– cohort of TBCRC-053 (P-RAD): a randomized trial of no, low, or high dose preoperative radiation with pembrolizumab (Keytruda) and chemotherapy in node-positive, HER2-negative breast cancer

RF3-07: A multimodal-multitask deep learning model trained in NSABP B-42 and validated in TAILORx for late distant recurrence risk in HR+ early breast cancer

What Are the Top Abstracts to Watch in HR+ Advanced Breast Cancer at SABCS 2025?

Poll 2: Which of these HR+ advanced breast cancer abstracts are you most anticipating at SABCS 2025?

Vote Now: X | LinkedIn

GS1-09: Sacituzumab govitecan vs chemotherapy as first therapy after endocrine therapy in HR+/HER2− (IHC 0, 1+, 2+/ISH−) metastatic breast cancer: primary results from ASCENT-07

RF7-01: Elacestrant (Orserdu) in combination with everolimus or abemaciclib (Verzenio) in patients with ER+/HER2– locally advanced or metastatic breast cancer: phase 2 results from ELEVATE, an open-label, umbrella study

RF7-04: Gedatolisib, a multi-target PI3K/AKT/mTOR (PAM) inhibitor, plus fulvestrant (Faslodex) with or without palbociclib (Ibrance) for second-line treatment of patients with HR+/HER2–/PIK3CA-wild type advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial

GS3-09: Clinical and biomarker subgroup analysis of evERA breast cancer: a phase 3 trial of giredestrant plus everolimus in patients with ER+, HER2– advanced breast cancer previously treated with a CDK4/6 inhibitor

What Are the Top Abstracts to Watch in HER2+ Breast Cancer at SABCS 2025?

Poll 3: Which of these HER2+ breast cancer abstracts are you most anticipating at SABCS 2025?

Vote Now: X | LinkedIn

GS1-01: HER2CLIMB-05: a randomized, double-blind, phase 3 study of tucatinib (Tukysa) vs placebo in combination with trastuzumab (Herceptin) and pertuzumab (Perjeta) as maintenance therapy for HER2+ metastatic breast cancer

RF6-01: Trastuzumab deruxtecan (T-DXd; Enhertu) vs trastuzumab emtansine (T-DM1; Kadcyla) in patients with high-risk HER2+ primary breast cancer with residual invasive disease after neoadjuvant therapy: interim analysis of DESTINY-Breast05

RF6-07: Trastuzumab deruxtecan plus pertuzumab vs taxane plus trastuzumab plus pertuzumab for first-line treatment of patients with HER2+ advanced/metastatic breast cancer: patient-reported outcomes from the DESTINY-Breast09 study

GS1-03: Adjuvant aromatase inhibitor or tamoxifen (Soltamox) in patients with HR+/HER2+ early breast cancer: an exploratory analysis from the ALTTO (BIG 2-06) trial

What Are the Top Abstracts to Watch in TNBC at SABCS 2025?

Poll 4: Which of these abstracts in TNBC are you most anticipating at SABCS 2025?

Vote Now: X | LinkedIn

RF6-05: Patient-reported outcomes with sacituzumab govitecan (Trodelvy) vs chemotherapy in patients with previously untreated advanced TNBC who are not candidates for PD-(L)1 inhibitors in the phase 3 ASCENT-03 study

RF4-03: Evaluation of a whole-exome sequencing tumor-informed circulating tumor DNA measurable residual disease assay in patients with early TNBC receiving neoadjuvant chemotherapy with or without atezolizumab (Tecentriq): a prospective sub study of the NSABP-B59/GBG-96-GeparDouze Trial

PS5-02-28: Safety analysis of phase 3 ASCENT-04 study of sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab for previously untreated PD-L1+ metastatic TNBC

RF2-01: Prognostic markers in residual tumors after neoadjuvant chemotherapy for early TNBC: a pooled analysis from 9 neoadjuvant GBG/AGO-B Trials

What Are the Other Top Abstracts to Watch in Breast Cancer at SABCS 2025?

Poll 4: Which of these abstracts in TNBC are you most anticipating at SABCS 2025?

Vote Now: X | LinkedIn

GS3-01: Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2

GS3-03: Randomized controlled trial of Young, Empowered, and Strong (YES), an mHealth intervention for adolescent and young adult breast cancer survivors

GS3-04: Effects of acupuncture vs sham acupuncture and usual care on cancer-related cognitive difficulties among breast cancer survivors: the ENHANCE randomized clinical tria

GS3-02: Fertility and ovarian function preservation in premenopausal women with early breast cancer: results from the multicenter prospective PREgnancy and FERtility (PREFER) study

By voting in these polls, you’ll help inform our coverage and ensure we bring you the most important news from SABCS 2025. The meeting offers a platform for clinicians, researchers, patient advocates, journalists, and health care industry representatives to meet, share, and learn about the latest in breast cancer, from groundbreaking discoveries to cutting-edge treatments.